Pharmacology and Structural Analysis of Ligand Binding to the Orthosteric Site of Glutamate-Like GluD2 Receptors

Research output: Contribution to journalJournal articleResearchpeer-review

Standard

Pharmacology and Structural Analysis of Ligand Binding to the Orthosteric Site of Glutamate-Like GluD2 Receptors. / Kristensen, Anders S; Hansen, Kasper B; Naur, Peter; Olsen, Lars; Kurtkaya, Natalie L; Dravid, Shashank M; Kvist, Trine; Yi, Feng; Pøhlsgaard, Jacob; Clausen, Rasmus P; Gajhede, Michael; Kastrup, Jette S; Traynelis, Stephen F.

In: Molecular Pharmacology, Vol. 89, No. 2, 02.2016, p. 253-262.

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Kristensen, AS, Hansen, KB, Naur, P, Olsen, L, Kurtkaya, NL, Dravid, SM, Kvist, T, Yi, F, Pøhlsgaard, J, Clausen, RP, Gajhede, M, Kastrup, JS & Traynelis, SF 2016, 'Pharmacology and Structural Analysis of Ligand Binding to the Orthosteric Site of Glutamate-Like GluD2 Receptors', Molecular Pharmacology, vol. 89, no. 2, pp. 253-262. https://doi.org/10.1124/mol.115.100909

APA

Kristensen, A. S., Hansen, K. B., Naur, P., Olsen, L., Kurtkaya, N. L., Dravid, S. M., Kvist, T., Yi, F., Pøhlsgaard, J., Clausen, R. P., Gajhede, M., Kastrup, J. S., & Traynelis, S. F. (2016). Pharmacology and Structural Analysis of Ligand Binding to the Orthosteric Site of Glutamate-Like GluD2 Receptors. Molecular Pharmacology, 89(2), 253-262. https://doi.org/10.1124/mol.115.100909

Vancouver

Kristensen AS, Hansen KB, Naur P, Olsen L, Kurtkaya NL, Dravid SM et al. Pharmacology and Structural Analysis of Ligand Binding to the Orthosteric Site of Glutamate-Like GluD2 Receptors. Molecular Pharmacology. 2016 Feb;89(2):253-262. https://doi.org/10.1124/mol.115.100909

Author

Kristensen, Anders S ; Hansen, Kasper B ; Naur, Peter ; Olsen, Lars ; Kurtkaya, Natalie L ; Dravid, Shashank M ; Kvist, Trine ; Yi, Feng ; Pøhlsgaard, Jacob ; Clausen, Rasmus P ; Gajhede, Michael ; Kastrup, Jette S ; Traynelis, Stephen F. / Pharmacology and Structural Analysis of Ligand Binding to the Orthosteric Site of Glutamate-Like GluD2 Receptors. In: Molecular Pharmacology. 2016 ; Vol. 89, No. 2. pp. 253-262.

Bibtex

@article{54dc45c8c7b448d5bf62498fc7d90dda,
title = "Pharmacology and Structural Analysis of Ligand Binding to the Orthosteric Site of Glutamate-Like GluD2 Receptors",
abstract = "The GluD2 receptor is a fundamental component of postsynaptic sites in Purkinje neurons, and is required for normal cerebellar function. GluD2 and the closely related GluD1 are classified as members of the ionotropic glutamate receptor (iGluR) superfamily on the basis of sequence similarity, but do not bind l-glutamate. The amino acid neurotransmitter D-Ser is a GluD2 receptor ligand, and endogenous D-Ser signaling through GluD2 has recently been shown to regulate endocytosis of α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid-type iGluRs during synaptic plasticity in the cerebellum, such as long-term depression. Here, we investigate the pharmacology of the orthosteric binding site in GluD2 by examining the activity of analogs of D-Ser and GluN1 glycine site competitive antagonists at GluD2 receptors containing the lurcher mutation (GluD2(LC)), which promotes spontaneous channel activation. We identify several compounds that modulate GluD2(LC), including a halogenated alanine analog as well as the kynurenic acid analog 7-chloro-4-oxo-1H-quinoline-2-carboxylic acid (7-chlorokynurenic acid; 7-CKA). By correlating thermodynamic and structural data for 7-CKA binding to the isolated GluD2 ligand binding domain (GluD2-LBD), we find that binding 7-CKA to GluD2-LBD differs from D-Ser by inducing an intermediate cleft closure of the clamshell-shaped LBD. The GluD2 ligands identified here can potentially serve as a starting point for development of GluD2-selective ligands useful as tools in studies of the signaling role of the GluD2 receptor in the brain.",
author = "Kristensen, {Anders S} and Hansen, {Kasper B} and Peter Naur and Lars Olsen and Kurtkaya, {Natalie L} and Dravid, {Shashank M} and Trine Kvist and Feng Yi and Jacob P{\o}hlsgaard and Clausen, {Rasmus P} and Michael Gajhede and Kastrup, {Jette S} and Traynelis, {Stephen F}",
note = "Copyright {\textcopyright} 2016 by The American Society for Pharmacology and Experimental Therapeutics.",
year = "2016",
month = feb,
doi = "10.1124/mol.115.100909",
language = "English",
volume = "89",
pages = "253--262",
journal = "Molecular Pharmacology",
issn = "0026-895X",
publisher = "American Society for Pharmacology and Experimental Therapeutics",
number = "2",

}

RIS

TY - JOUR

T1 - Pharmacology and Structural Analysis of Ligand Binding to the Orthosteric Site of Glutamate-Like GluD2 Receptors

AU - Kristensen, Anders S

AU - Hansen, Kasper B

AU - Naur, Peter

AU - Olsen, Lars

AU - Kurtkaya, Natalie L

AU - Dravid, Shashank M

AU - Kvist, Trine

AU - Yi, Feng

AU - Pøhlsgaard, Jacob

AU - Clausen, Rasmus P

AU - Gajhede, Michael

AU - Kastrup, Jette S

AU - Traynelis, Stephen F

N1 - Copyright © 2016 by The American Society for Pharmacology and Experimental Therapeutics.

PY - 2016/2

Y1 - 2016/2

N2 - The GluD2 receptor is a fundamental component of postsynaptic sites in Purkinje neurons, and is required for normal cerebellar function. GluD2 and the closely related GluD1 are classified as members of the ionotropic glutamate receptor (iGluR) superfamily on the basis of sequence similarity, but do not bind l-glutamate. The amino acid neurotransmitter D-Ser is a GluD2 receptor ligand, and endogenous D-Ser signaling through GluD2 has recently been shown to regulate endocytosis of α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid-type iGluRs during synaptic plasticity in the cerebellum, such as long-term depression. Here, we investigate the pharmacology of the orthosteric binding site in GluD2 by examining the activity of analogs of D-Ser and GluN1 glycine site competitive antagonists at GluD2 receptors containing the lurcher mutation (GluD2(LC)), which promotes spontaneous channel activation. We identify several compounds that modulate GluD2(LC), including a halogenated alanine analog as well as the kynurenic acid analog 7-chloro-4-oxo-1H-quinoline-2-carboxylic acid (7-chlorokynurenic acid; 7-CKA). By correlating thermodynamic and structural data for 7-CKA binding to the isolated GluD2 ligand binding domain (GluD2-LBD), we find that binding 7-CKA to GluD2-LBD differs from D-Ser by inducing an intermediate cleft closure of the clamshell-shaped LBD. The GluD2 ligands identified here can potentially serve as a starting point for development of GluD2-selective ligands useful as tools in studies of the signaling role of the GluD2 receptor in the brain.

AB - The GluD2 receptor is a fundamental component of postsynaptic sites in Purkinje neurons, and is required for normal cerebellar function. GluD2 and the closely related GluD1 are classified as members of the ionotropic glutamate receptor (iGluR) superfamily on the basis of sequence similarity, but do not bind l-glutamate. The amino acid neurotransmitter D-Ser is a GluD2 receptor ligand, and endogenous D-Ser signaling through GluD2 has recently been shown to regulate endocytosis of α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid-type iGluRs during synaptic plasticity in the cerebellum, such as long-term depression. Here, we investigate the pharmacology of the orthosteric binding site in GluD2 by examining the activity of analogs of D-Ser and GluN1 glycine site competitive antagonists at GluD2 receptors containing the lurcher mutation (GluD2(LC)), which promotes spontaneous channel activation. We identify several compounds that modulate GluD2(LC), including a halogenated alanine analog as well as the kynurenic acid analog 7-chloro-4-oxo-1H-quinoline-2-carboxylic acid (7-chlorokynurenic acid; 7-CKA). By correlating thermodynamic and structural data for 7-CKA binding to the isolated GluD2 ligand binding domain (GluD2-LBD), we find that binding 7-CKA to GluD2-LBD differs from D-Ser by inducing an intermediate cleft closure of the clamshell-shaped LBD. The GluD2 ligands identified here can potentially serve as a starting point for development of GluD2-selective ligands useful as tools in studies of the signaling role of the GluD2 receptor in the brain.

U2 - 10.1124/mol.115.100909

DO - 10.1124/mol.115.100909

M3 - Journal article

C2 - 26661043

VL - 89

SP - 253

EP - 262

JO - Molecular Pharmacology

JF - Molecular Pharmacology

SN - 0026-895X

IS - 2

ER -

ID: 156078325